.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, individuals along with metastatic stomach growths that acquired biomarker-matched treatments based upon flowing lump DNA profiling showed a greater medical benefit than those acquiring unmatched therapy.